Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijcard.2020.10.028 http://scihub22266oqcxt.onion/10.1016/j.ijcard.2020.10.028 33075384!7566676!33075384     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Cardiol 2021 ; 324 (ä): 255-260 Nephropedia Template TP {{tp|p=33075384|t=2021. Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19 An alleged past-resolved problem |pdf=|usr=}}{{33075384}} gab.com Text Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19 An alleged past-resolved problem JO: Int J Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=33075384 #FOAvip The antiretroviral drug lopinavir/ritonavir has been recently repurposed for the treatment of COVID-19. Its empirical use has been associated with multiple cardiac adverse reactions pertaining to its ancillary multi-channel blocking properties, vaguely characterized until now. We aimed to characterize qualitatively the cardiotoxicity associated with lopinavir/ritonavir in the setting of COVID-19. Spontaneous notifications of cardiac adverse drug reactions reported to the national Pharmacovigilance Network were collected for 8 weeks since March 1st 2020. The Nice Regional Center of Pharmacovigilance, whose scope of expertise is drug-induced long QT syndrome, analyzed the cases, including the reassessment of all available ECGs. QTc >/= 500 ms and delta QTc > 60 ms from baseline were deemed serious. Twenty-two cases presented with 28 cardiac adverse reactions associated with the empirical use of lopinavir/ritonavir in a hospital setting. Most adverse reactions reflected lopinavir/ritonavir potency to block voltage-gated potassium channels with 5 ventricular arrhythmias and 17 QTc prolongations. An average QTc augmentation of 97 +/- 69 ms was reported. Twelve QTc prolongations were deemed serious. Other cases were likely related to lopinavir/ritonavir potency to block sodium channels: 1 case of bundle branch block and 5 recurrent bradycardias. The incidence of cardiac adverse reactions of lopinavir/ritonavir was estimated between 0.3% and 0.4%. These cardiac adverse drug reactions offer a new insight in its ancillary multi-channel blocking functions. Lopinavir/ritonavir cardiotoxicity may be of concern for its empirical use during the COVID-19 pandemic. Caution should be exerted relative to this risk where lopinavir/ritonavir summary of product characteristics should be implemented accordingly. Twit Text FOAVip Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19 An alleged past-resolved problem ????Int J Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=33075384 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33075384 #FOAvip English Wikipedia <ref>{{Cite pmid|33075384}}</ref> Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19 An alleged past-resolved problem #MMPMID33075384 Fresse A; Viard D; Romani S; Gerard A; Lepelley M; Rocher F; Salem JE; Drici MD Int J Cardiol 2021[Feb]; 324 (ä): 255-260 PMID33075384show ga The antiretroviral drug lopinavir/ritonavir has been recently repurposed for the treatment of COVID-19. Its empirical use has been associated with multiple cardiac adverse reactions pertaining to its ancillary multi-channel blocking properties, vaguely characterized until now. We aimed to characterize qualitatively the cardiotoxicity associated with lopinavir/ritonavir in the setting of COVID-19. Spontaneous notifications of cardiac adverse drug reactions reported to the national Pharmacovigilance Network were collected for 8 weeks since March 1st 2020. The Nice Regional Center of Pharmacovigilance, whose scope of expertise is drug-induced long QT syndrome, analyzed the cases, including the reassessment of all available ECGs. QTc >/= 500 ms and delta QTc > 60 ms from baseline were deemed serious. Twenty-two cases presented with 28 cardiac adverse reactions associated with the empirical use of lopinavir/ritonavir in a hospital setting. Most adverse reactions reflected lopinavir/ritonavir potency to block voltage-gated potassium channels with 5 ventricular arrhythmias and 17 QTc prolongations. An average QTc augmentation of 97 +/- 69 ms was reported. Twelve QTc prolongations were deemed serious. Other cases were likely related to lopinavir/ritonavir potency to block sodium channels: 1 case of bundle branch block and 5 recurrent bradycardias. The incidence of cardiac adverse reactions of lopinavir/ritonavir was estimated between 0.3% and 0.4%. These cardiac adverse drug reactions offer a new insight in its ancillary multi-channel blocking functions. Lopinavir/ritonavir cardiotoxicity may be of concern for its empirical use during the COVID-19 pandemic. Caution should be exerted relative to this risk where lopinavir/ritonavir summary of product characteristics should be implemented accordingly. |*COVID-19 Drug Treatment[MESH] |*Pharmacovigilance[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19/diagnosis/*epidemiology[MESH] |Cardiotoxicity/diagnosis/*epidemiology[MESH] |Drug Combinations[MESH] |Electrocardiography/drug effects/trends[MESH] |Female[MESH] |France/epidemiology[MESH] |HIV Protease Inhibitors/administration & dosage/adverse effects[MESH] |Humans[MESH] |Long QT Syndrome/chemically induced/diagnosis/epidemiology[MESH] |Lopinavir/*administration & dosage/*adverse effects[MESH] |Male[MESH] |Middle Aged[MESH] |Potassium Channel Blockers/administration & dosage/adverse effects[MESH]Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in (epmc).pdf DeepDyve Pubget Overpricing